HOOKIPA to Present at the SVB Leerink Global Healthcare Conference
09 févr. 2022 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Feb. 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
18 janv. 2022 07h00 HE
|
HOOKIPA Pharma Inc.
First patient dosed with HB-200 and pembrolizumab combination for treatment of 1st-line advanced/metastatic head and neck cancer in Phase 2 arm of ongoing Phase 1/2 trial Fast Track Designation...
HOOKIPA Pharma to Present at the H.C. Wainwright BioConnect Conference
04 janv. 2022 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Jan. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Participate in the JMP Securities Hematology and Oncology Summit
03 déc. 2021 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Dec. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Participate in Upcoming Stifel 2021 Virtual Healthcare Conference
12 nov. 2021 07h00 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Nov. 12, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma Reports Third Quarter 2021 Financial Results and Recent Highlights
10 nov. 2021 06h30 HE
|
HOOKIPA Pharma Inc.
Clinical collaboration with Merck & Co., Inc., Kenilworth, NJ, USA, set to evaluate HB-201 in combination with pembrolizumab in 1st- and 2nd-line HNSCC patientsBased on recent strong data updates,...
HOOKIPA advances HB-200 program to Phase 2 and prioritizes oncology portfolio based on clinical data updates across its novel arenaviral platform
09 nov. 2021 16h01 HE
|
HOOKIPA Pharma Inc.
Based on positive interim Phase 1 data, HOOKIPA initiates Phase 2 study to assess HB-201 in combination with pembrolizumab in 1st and 2nd line head and neck cancerInterim Phase 1 HB-200 data continue...
HOOKIPA Pharma to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
03 nov. 2021 08h18 HE
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Nov. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA announces publication on the benefits of its novel arenaviral immunotherapeutics in cancer in Frontiers in Oncology
14 oct. 2021 07h00 HE
|
HOOKIPA Pharma Inc.
Comprehensive review highlights potential of HOOKIPA’s versatile arenavirus platform as a new immunotherapy strategy to address critical unmet needs in cancerPre-clinical and clinical data showcase...
HOOKIPA announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced head and neck cancers
15 sept. 2021 07h00 HE
|
HOOKIPA Pharma Inc.
Clinical collaboration to assess HB-200 in combination with KEYTRUDA® (pembrolizumab) as first-line treatmentHOOKIPA poised to advance clinical development program with randomized Phase 2 study in...